Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis
Steven E. Nissen(Cleveland Clinic), for the ASTEROID Investigators, Peter Libby(Harvard University), Valerie A. Cain(AstraZeneca (United Kingdom)), Jean‐Claude Tardif(Montreal Heart Institute), Christie M. Ballantyne(Baylor College of Medicine), Stephen J. Nicholls(Australian Centre for Heart Health), Paul Schoenhagen(Cleveland Clinic), E. Murat Tuzcu(Cleveland Clinic), Marlene Goormastic(Cleveland Clinic), Raimund Erbel(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Jean Charles Fruchart(Université de Lille), Kathy Wolski(Cleveland Clinic), Tim Crowe(Cleveland Clinic), Joel S. Raichlen(AstraZeneca (United Kingdom)), Jean Davignon(Université de Montréal), İlke Sipahi(Cleveland Clinic)
Cited by 2,036
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Inflammation in Atherosclerosis
|Arteriosclerosis Thrombosis and Vascular Biology|2012|3.7k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k